13F Data
13F filer · CIK 882095

GILEAD SCIENCES, INC.

FOSTER CITY, CA · filing since Q4 2024 · last filing Nov 6, 2026
Reported value
$1.5B
$-184.9M vs prior
Positions
5
New / sold out
0 / 0
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $0
Top-10 weight
100.0%

Biggest buys vs Q2 2026

No new or increased positions this quarter.

Biggest sells vs Q2 2026

No reduced or sold positions this quarter.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2024: $1.6BQ1 2025: $1.2BQ2 2025: $1.3BQ3 2025: $1.8BQ4 2025: $1.9BQ1 2026: $2.1BQ2 2026: $1.6BQ3 2026: $1.5B
Q4 2024Q3 2026

Holdings · Q3 2026

#SecuritySharesValueWeight
1Arcus Biosciences Inc.COM31,424,760$811.7M55.45%
2Lakefront BiotherapeuticsSPON ADR16,707,477$501.3M34.24%
3Assembly Biosciences Inc.COM NEW4,977,089$116.9M7.99%
4Kyverna Therapeutics Inc.COM4,126,119$28.1M1.92%
5Xilio Therapeutics Inc.COM650,389$5.9M0.40%